Aptamer Group, Ltd. the developer of Optimizer® binders to enable innovation in the life science industry, and BizCom Japan, Inc., a Japan-based trading and consulting company, today announced that they have entered into a distribution and marketing agreement .
This agreement gives BizCom non-exclusive rights to market and sell Optimer’s discovery and development services in Japan.
The Optimer platform consists of three integrated discovery processes which together increase the potential target range of Optimer binders. These nucleic acid-based affinity ligands offer a range of benefits to scientists, including faster discovery, increased batch consistency, and increased stability, eliminating the need for freezers and providing a longer shelf life than protein-based alternatives.
BizCom Japan, Inc. will use its extensive experience and expertise in life science sales and marketing in Japan to market Aptamer Group services in the region.
We are excited to partner with BizCom Japan to establish a clear path to the Optimer Discovery Services market in Japan, one of the largest pharmaceutical and medical markets. This is an important market for the Aptamer Group; BizCom Japan is a great partner and is associated with well known and established suppliers. It enjoys an excellent reputation for customer support and an extensive network throughout Japan.
Dr Arron Tolley, Chairman and CEO, Aptamer Group
We are happy to distribute customized Optimer services to the Japanese market. Optimer binders are unique affinity ligands exhibiting specific binding activity, stability, and offering new solutions to researchers that cannot be obtained with alternative ligands, such as antibodies. We are excited to bring this new technology to scientists in Japan, to provide further support to the life sciences market. “
Dr Hiroyasu Nakatani, Executive General Manager, BizCom Japan